Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer

Phase 1

Withdrawn

Conditions: Primary Peritoneal Carcinoma
Ovarian Carcinoma, Stage 3 or 4
Epithelial Ovarian Carcinoma

Interventions: Drug: Paclitaxel
Drug: N-acetylcysteine
Drug: Cisplatin

First Posted Date: 2010-06-07

Last Posted Date: 2017-04-21

Lead Sponsor: OHSU Knight Cancer Institute

Registration Number: NCT01138137

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Neoplasms

Interventions: Drug: BI 6727
Drug: Paclitaxel
Drug: Gemcitabine
Drug: Topotecan
Drug: Pegylated liposomal doxorubicin (PLD)

First Posted Date: 2010-05-12

Last Posted Date: 2015-08-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 110

Registration Number: NCT01121406

Locations: 🇧🇪
1230.18.32003 Boehringer Ingelheim Investigational Site, Brussel, Belgium
🇧🇪
1230.18.32004 Boehringer Ingelheim Investigational Site, Edegem, Belgium
🇧🇪
1230.18.32002 Boehringer Ingelheim Investigational Site, Gent, Belgium

and more 28 locations

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: docetaxel
Drug: pertuzumab
Drug: pertuzumab-placebo
Drug: paclitaxel
Drug: trastuzumab emtansine
Drug: trastuzumab [Herceptin]

First Posted Date: 2010-05-10

Last Posted Date: 2024-03-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1095

Registration Number: NCT01120184

Locations: 🇹🇭
Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand
🇹🇷
Gazi Uni Medical Faculty Hospital; Oncology Dept, Ankara, Turkey
🇬🇧
Bristol Haematology and Oncology centre, Bristol, United Kingdom

and more 254 locations

Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Bevacizumab
Drug: Paclitaxel

First Posted Date: 2010-05-10

Last Posted Date: 2017-02-23

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 46

Registration Number: NCT01120158

Locations: 🇬🇷
"Marika Iliadis" Hospital of Athens, Dep of Medical Oncology, Athens, Greece
🇬🇷
"Metaxa's" Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology, Athens, Greece
🇬🇷
State General Hospital of Larissa, Dep of Medical Oncology, Larissa, Greece

and more 8 locations

A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)

Phase 1

Terminated

Conditions: Cancer: Solid Tumors

Interventions: Drug: MK-4827
Drug: carboplatin
Drug: liposomal doxorubicin
Drug: paclitaxel

First Posted Date: 2010-04-26

Last Posted Date: 2016-05-05

Lead Sponsor: Tesaro, Inc.

Target Recruit Count: 12

Registration Number: NCT01110603

Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

Phase 2

Completed

Conditions: Bladder Cancer
Bladder (Urothelial, Transitional Cell) Cancer
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)
Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable

Interventions: Drug: Pazopanib (GW786034)
Drug: Paclitaxel

First Posted Date: 2010-04-21

Last Posted Date: 2017-06-09

Lead Sponsor: Sandy Srinivas

Target Recruit Count: 43

Registration Number: NCT01108055

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Biological: Bevacizumab
Drug: Pemetrexed Disodium Heptahydrate

First Posted Date: 2010-04-21

Last Posted Date: 2023-07-07

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 1516

Registration Number: NCT01107626

Locations: 🇺🇸
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Frankford Hospital Cancer Center - Torresdale Campus, Philadelphia, Pennsylvania, United States
🇺🇸
Albert Einstein Cancer Center, Philadelphia, Pennsylvania, United States

and more 430 locations

Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery

Phase 2

Completed

Conditions: Stage IA Breast Cancer
Stage IB Breast Cancer
Stage IIA Breast Cancer
Stage IIB Breast Cancer

Interventions: Drug: cyclophosphamide
Drug: paclitaxel
Biological: trastuzumab
Other: laboratory biomarker analysis

First Posted Date: 2010-04-20

Last Posted Date: 2023-09-28

Lead Sponsor: University of Nebraska

Target Recruit Count: 112

Registration Number: NCT01106898

Locations: 🇺🇸
Saint Francis Medical Center, Grand Island, Nebraska, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)

Phase 1

Completed

Conditions: NSCLC
Solid Tumors

Interventions: Drug: YM155
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2010-04-09

Last Posted Date: 2015-10-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT01100931

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Phase 2

Completed

Conditions: Fallopian Tube Transitional Cell Carcinoma
FIGO Stage III Ovarian Cancer
FIGO Stage IIIA1 Ovarian Cancer
FIGO Stage IVB Ovarian Cancer
Ovarian Serous Adenocarcinoma
Fallopian Tube Undifferentiated Carcinoma
FIGO Stage IIIA1(i) Ovarian Cancer
FIGO Stage IIIA1(ii) Ovarian Cancer
FIGO Stage IIIC Ovarian Cancer
Ovarian Seromucinous Carcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2010-04-02

Last Posted Date: 2022-10-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 33

Registration Number: NCT01097746

Locations: 🇺🇸
MD Anderson Regional Care Center-Sugar Land, Sugar Land, Texas, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
MD Anderson Regional Care Center-Katy, Houston, Texas, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy